Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nenocorilant · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1a: Nenocorilant 200 mg and Nivolumab | EXPERIMENTAL | Cohort 1a: Patients will receive nenocorilant 200 mg orally under fed conditions once daily, and nivolumab 240 mg IV every 2 weeks. After 3 months of treatment, patients may choose to switch the nivolumab regimen to 480 mg IV every 4 weeks if the nenocorilant nivolumab combination is tolerated. |
| Cohort 1b: Nenocorilant 300 mg and Nivolumab | EXPERIMENTAL | Cohort 1b: Patients will receive nenocorilant 300 mg orally under fed conditions once daily, and nivolumab 240 mg IV every 2 weeks. After 3 months of treatment, patients may choose to switch the nivolumab regimen to 480 mg IV every 4 weeks if the nenocorilant nivolumab combination is tolerated. |
| Cohort 1c: Nenocorilant 400 mg and Nivolumab | EXPERIMENTAL | Cohort 1c: Patients will receive nenocorilant 400 mg orally under fed conditions once daily, and nivolumab 240 mg IV every 2 weeks. After 3 months of treatment, patients may choose to switch the nivolumab regimen to 480 mg IV every 4 weeks if the nenocorilant nivolumab combination is tolerated. |
| Name | Type | Description |
|---|---|---|
| Nenocorilant 200 mg | DRUG | Nenocorilant 200 mg will be supplied as 50 and/or 100 mg tablets. |
| Nenocorilant 300 mg | DRUG | Nenocorilant 300 mg will be supplied as 50 and/or 100 mg tablets. |
| Nenocorilant 400 mg | DRUG | Nenocorilant 400 mg will be supplied as 50 and/or 100 mg tablets. |
| Nivolumab | DRUG | Nivolumab 240 mg and 480 mg will be supplied as single-dose 120 mg/12 mL (10 mg/mL) vials. |
Inclusion Criteria: Part 1 * Signed and dated institutional review board (IRB)/ independent ethics committee (IEC)-approved informed consent form (ICF) * Has solid malignancies that have received all available standard therapies for the specific tumor type or for which no standard therapy exists, ...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
Nenocorilant is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be cancerous. It is currently in Phase 1 clinical development for this oncology indication.
Nenocorilant targets the glucocorticoid receptor (GR). By targeting GR, the drug is being investigated for its potential role in treating neoplasms, though its exact mechanism of action in this context is still under study.
Nenocorilant is being developed by Corcept Therapeutics Incorporated, a biopharmaceutical company. The company's stock is traded under the ticker symbol CORT.
Nenocorilant is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being evaluated for safety and efficacy in clinical trials.
Nenocorilant is being studied in a Phase 1 clinical trial with the identifier NCT07276373. This trial is titled 'Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies' and is currently recruiting participants in the United States.